The Clinical Study Of Acute Carotisal Cerebral Infarction Treated By Human Urinary Kallidinogenase

Objective: To investigate the effect and safety of a new drug, urinary kallidinogenase combined with citicoline in the treament of acute carotisal cerebral infarction.Method: 64 cases with acute carotisal cerebral infarction were divided into two groups based on routine treatment randomly:citicoline group(n=32)and urinary kallidinogenase combined with citicoline group(n=32).citicoline group was treated with citicoline for 14 days and combined group was treated with citicoline 75mg/d, and urinary kallidinogenase 0.15PNA for 14 days.The neurological deficit scores(NDS),BI index and adverse reactions were evaluated before and after the treatment,respectively.Results:After the treatment,the scores of NDS and BI index were significantly decreased in two groups than those before the treatment(p<0.01),and kallidnogenase combined with citicoline group was much better than citicoline group.There was no obvious adverse reaction in two groups. The blood pressure drop quickly restoring soon after the withdrawal of kallidinogenas e and use of hemopiesie drugs,was considered to be caused by the combination use of anti—hypertensive drug ACEI and quick infusion speed.Conclusion: A large number of clinical and experimental studies have suggested that the human tisse kallikrein(HTK) has the effects of neuroprotection,such as dilating brain arteries,enhancing neovascularization in ischemic brain,promoting neuroglial cell migration,inhibiting apoptosis,and reducing inflammatory cell infiltration,etc. Kallidinogenase combined with citicoline shows better clinic effect and no more hemorrhagic risk than citicoline in the therapy of acute carotisal cerebral infarction. Kallidinogenase is eficacious for acute brain infarction in improving the neurological deficits which is safe in clinical use.